Ondansetron Pediatric Dose — Antiemetic for Nausea & Vomiting
Ondansetron is a selective serotonin 5-HT₃ receptor antagonist that blocks peripheral and central serotonergic signaling involved in the vomiting reflex. It is widely used in pediatric practice for the prevention and treatment of nausea and vomiting associated with gastroenteritis, chemotherapy, and postoperative recovery. Its availability in both intravenous and oral formulations makes it a versatile first-line antiemetic across a range of clinical settings.
Pediatric Dosing
- Dose: 0.15 mg/kg/dose IV or PO every 8 hours as needed
- Maximum single dose: 8 mg
Doses should be rounded to a practical measurable volume or tablet strength based on available formulations. Administer no more frequently than every 8 hours on a PRN basis; scheduled routine dosing should be guided by clinical indication and institutional protocol.
Worked example: For a 20 kg child: 20 × 0.15 mg/kg = 3 mg per dose. For a 60 kg adolescent: 60 × 0.15 mg/kg = 9 mg, capped at the maximum of 8 mg per dose.
Indications and Clinical Context
Ondansetron is indicated for the management of nausea and vomiting in pediatric patients across multiple contexts, including acute gastroenteritis, postoperative nausea and vomiting (PONV), and chemotherapy-induced nausea and vomiting (CINV). In the emergency department setting, a single oral dose has been shown to reduce vomiting episodes and improve oral rehydration success in children with gastroenteritis, decreasing the need for intravenous fluid administration and hospitalization.
Standard pediatric clinical guidelines and institutional antiemetic protocols support weight-based dosing at 0.15 mg/kg per dose. Clinicians should consider the underlying etiology of vomiting before initiating antiemetic therapy, as suppression of symptoms may mask serious pathology such as increased intracranial pressure or surgical abdomen.
Administration and Monitoring
Ondansetron may be administered intravenously as a slow IV push over 2–5 minutes or diluted and infused over 15 minutes to reduce the risk of QT prolongation and infusion-related effects. The orally disintegrating tablet (ODT) formulation is particularly useful in patients with active vomiting who cannot reliably swallow standard tablets. The oral solution provides flexible weight-based dosing in younger children.
- Routes: IV (slow push or infusion) or PO (tablet, ODT, or oral solution)
- Maximum single dose: 8 mg — doses should not exceed this regardless of weight
- Key adverse effects: Headache, constipation, transient QT interval prolongation (ECG monitoring recommended with IV use in at-risk patients)
- Contraindications/cautions: Use with caution in patients with congenital long QT syndrome or those receiving other QT-prolonging agents; consult institutional protocol for dose adjustments in hepatic impairment
Disclaimer: This article is an educational reference summarizing standard pediatric dosing values. It is not a substitute for clinical judgment. Always verify doses against institutional protocols, the current edition of authoritative references (e.g., Lexicomp, Harriet Lane Handbook, PALS guidelines), the patient’s accurate weight, and any patient-specific factors (renal/hepatic function, allergies, comedications) before administration.